濟民醫療(603222.SH):2021年度扣非淨利預增348.58%-415.26%
格隆匯1月17日丨濟民醫療(603222.SH)公佈2021年年度業績預吿,公司預計2021年度歸屬於上市公司股東的淨利潤為1.4億元-1.55億元,與上年同期相比增加1.336億元-1.486億元。
公司預計2021年度歸屬於上市公司股東的扣除非經常性損益的淨利潤為1.01億元-1.16億元,與上年同期相比增加7840.29萬元-9340.29萬元,同比增長348.58%-415.26%(上年基數偏低導致增幅較大)。
業績變動的主要原因:
(一)公司全資子公司聚民生物科技有限公司安全注射器(針)產品全年實現銷售約6億支,實現淨利潤約15,220億元,較上年增長幅度較大;
(二)公司處置鄆城新友誼醫院有限公司確認投資收益約3800萬元,同時對應收股權回購款計提約2115萬元,該事項整體增加利潤約1685萬元;
(三)公司控股子公司鄂州二醫院有限公司對涉及的翁雄祥、姜松發民事訴訟案件已完結,公司衝回前期預提的訴訟損失約1126萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.